Drug Trial Radar · NCT02762578
Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes
Last checked: Nov 20, 2026Latest source record: Apr 2, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
543
Actual
Start
May 3, 2016
Primary completion
May 19, 2017
Study completion Jun 19, 2017
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- May 5, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is conducted in Asia. The aim of this trial is to compare efficacy and safety of insulin degludec/insulin aspart and BIAsp 30 in subjects with type 2 diabetes.
Conditions
- Diabetes
- Diabetes Mellitus, Type 2
Interventions
insulin degludec/insulin aspartDrug
Twice daily subcutaneous (sc, under the skin) injection.
biphasic insulin aspartDrug
Twice daily subcutaneous (sc, under the skin) injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in HbA1c (%) (Glycosylated Haemoglobin)Time frame: At 26 weeks
Locations
42 sites in 1 country. Site status is shown where the registry gives one.
Novo Nordisk Investigational Site
Tianjin, China
Novo Nordisk Investigational Site
Hefei, Anhui, China
Novo Nordisk Investigational Site
Hefei, Anhui, China
Novo Nordisk Investigational Site
Beijing, Beijing Municipality, China
Novo Nordisk Investigational Site
Beijing, Beijing Municipality, China
Novo Nordisk Investigational Site
Beijing, Beijing Municipality, China
Novo Nordisk Investigational Site
Beijing, Beijing Municipality, China
Novo Nordisk Investigational Site
Beijing, Beijing Municipality, China
Novo Nordisk Investigational Site
Beijing, Beijing Municipality, China
Novo Nordisk Investigational Site
Chongqing, Chongqing Municipality, China
Novo Nordisk Investigational Site
Chongqing, Chongqing Municipality, China
Novo Nordisk Investigational Site
Fuzhou, Fujian, China
Novo Nordisk Investigational Site
Fuzhou, Fujian, China
Novo Nordisk Investigational Site
Guangzhou, Guangdong, China
Novo Nordisk Investigational Site
Guangzhou, Guangdong, China
Novo Nordisk Investigational Site
Guangzhou, Guangdong, China
Novo Nordisk Investigational Site
Guangzhou, Guangdong, China
Novo Nordisk Investigational Site
Nanning, Guangxi, China
Novo Nordisk Investigational Site
Nanning, Guangxi, China
Novo Nordisk Investigational Site
Cangzhou, Hubei, China
Novo Nordisk Investigational Site
Baotou, Inner Mongolia, China
Novo Nordisk Investigational Site
Changzhou, Jiangsu, China
Novo Nordisk Investigational Site
Nanjing, Jiangsu, China
Novo Nordisk Investigational Site
Nanjing, Jiangsu, China
Novo Nordisk Investigational Site
Nanjing, Jiangsu, China
Novo Nordisk Investigational Site
Suzhou, Jiangsu, China
Novo Nordisk Investigational Site
Suzhou, Jiangsu, China
Novo Nordisk Investigational Site
Zhenjiang, Jiangsu, China
Novo Nordisk Investigational Site
Nanchang, Jiangxi, China
Novo Nordisk Investigational Site
Changchun, Jilin, China
Novo Nordisk Investigational Site
Changchun, Jilin, China
Novo Nordisk Investigational Site
Changchun, Jilin, China
Novo Nordisk Investigational Site
Siping, Jilin, China
Novo Nordisk Investigational Site
Jinan, Shandong, China
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Novo Nordisk Investigational Site
Chengdu, Sichuan, China
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.